Akram Dastagir, MD
Neurology · Golden Valley, MNNPI 1952616690
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $137,891 of the $174,466 with a category attached, or 79.0%. 37 manufacturers reported payments, led by TG Therapeutics, Inc. at 29.1% of the total. Reporting peaked in 2022 at $55,695 and has fallen 57.7% since, to $23,536 in 2025. Among neurology clinicians in MN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 279 payments — averaging $625.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- TG Therapeutics, Inc.$51K
- EMD Serono, Inc.$46K
- Biogen$28K
- AbbVie$18K
- E.r. Squibb & Sons, L.L.C.$10K
- Amgen$9K
- plus $13K from 31 others
Across 10 payments — averaging $8225.24 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$68K
- TG Therapeutics, Inc.$14K
What the payments were for
- Consulting fees$26,05615%
- Speaking & faculty fees$137,89179%
- Travel & lodging$5,6803%
- Food & beverage$4,8113%
- Education$290%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| TG Therapeutics, Inc. | 45 | $50,840 |
| EMD Serono, Inc. | 52 | $45,963 |
| Biogen | 32 | $27,842 |
| AbbVie | 23 | $17,547 |
| E.r. Squibb & Sons, L.L.C. | 10 | $9,864 |
| Amgen(2 entities) | 14 | $8,946 |
| Johnson & Johnson | 8 | $4,682 |
| Bristol Myers Squibb | 24 | $2,649 |
| Genentech USA, Inc. | 1 | $2,050 |
| Novartis | 9 | $2,009 |
| Janssen Scientific Affairs, LLC | 1 | $1,020 |
| Lilly USA, LLC | 6 | $110 |
| Lundbeck LLC | 6 | $88 |
| Catalyst Pharmaceuticals, Inc. | 4 | $84 |
| Amneal Pharmaceuticals LLC | 4 | $81 |
| Acadia Pharmaceuticals Inc | 4 | $63 |
| Teva Pharmaceuticals USA, Inc. | 4 | $62 |
| Sanofi | 2 | $53 |
| Neurelis, Inc. | 3 | $41 |
| Upsher-smith Laboratories LLC | 2 | $40 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $39 |
| Eisai Inc. | 2 | $38 |
| UCB, Inc. | 2 | $35 |
| Axsome Therapeutics, Inc. | 2 | $34 |
| Mylan Specialty L.p. | 2 | $31 |
| Vanda Pharmaceuticals Inc. | 2 | $28 |
| SK Life Science, Inc. | 2 | $28 |
| Pfizer | 2 | $27 |
| United Imaging Healthcare North America LLC | 1 | $25 |
| Jazz Pharmaceuticals Inc. | 1 | $23 |
| Kyowa Kirin, Inc. | 1 | $23 |
| Averitas Pharma Inc. | 1 | $21 |
| Greenwich Biosciences, Inc. | 1 | $19 |
| Octapharma USA, Inc. | 1 | $16 |
| CSL Behring | 1 | $16 |
| Argenx US, Inc. | 1 | $16 |
| Biohaven Pharmaceuticals, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$174,466 in reported general payments places this provider in the 95th percentile of 434 neurology providers in Minnesota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VumerityDiroximel Fumarate | 16 | $111,957 |
| Emgality PenGalcanezumab-Gnlm | 87 | $83,241 |
| UbrelvyUbrogepant | 32 | $70,649 |
| Nurtec OdtRimegepant Sulfate | 13 | $45,796 |
| GemtesaVibegron | 11 | $12,245 |
| Dalfampridine ErDalfampridine | 23 | $7,022 |
| Trospium Chloride ErTrospium Chloride | 13 | $3,702 |
| Modafinil | 12 | $3,323 |
| Gabapentin | 130 | $3,174 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 92 | $2,881 |
| Propranolol Hcl ErPropranolol Hcl | 35 | $2,123 |
| Lacosamide | 11 | $1,818 |
| Baclofen | 55 | $1,735 |
| Eletriptan HbrEletriptan Hydrobromide | 13 | $1,185 |
| RizatriptanRizatriptan Benzoate | 45 | $1,076 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| BiogenVumerity | $27,842 | $111,95716 claims |
| AbbVieUbrelvy | $17,547 | $70,64932 claims |
| PfizerNurtec Odt | $27 | $45,79613 claims |
| Upsher-smith Laboratories LLCTopiramate | $40 | $1,06687 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 434 neurology providers in Minnesota.
Other neurology in Golden Valley
- Jonathan CalkwoodGolden Valley$493K
- Irfan AltafullahGolden Valley$203K
- Jessica StulcGolden Valley$199K
- Jessica HeiringGolden Valley$149K
- Brent BerryGolden Valley$141K
- Joanne RoginGolden Valley$61K
- Xiaoming DongGolden Valley$47K
- Randall SchapiroGolden Valley$19K
- Jeffery AllenMinneapolis$1.1M
- Alejandro RabinsteinRochester$305K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.